で公開中です！詳しく見る

KARD

Kardigan Inc

KARD

時価総額 $12.2億

13.03 USD

-0.85

6.12%

終値時点更新済み 10月16日 16:00 EDT

プレマーケット

時間外取引

13.03

0.00

0%

1日

-6.12%

5日間

-11.3%

1か月

-24.73%

3か月

-38.01%

6か月

-40.77%

年初来

-40.77%

1年

-40.77%

5年間

-40.77%

10年間

-40.77%

概要： Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.

ヘルスケアバイオテクノロジー

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 25%

ニュートラル 75%

ネガティブ 0%

ニュートラル

Kardigan Announces Appointment of Kristin Reinke to its Board of Directors

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair of the Audit Committee.

Kardigan Announces Appointment of Kristin Reinke to its Board of Directors

ポジティブ

Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification

Kardigan targets genetic DCM, moderate CAVS, and post-hospitalization ASH with differentiated, biology-driven clinical programs. KARD holds $660.7M in liquid assets, providing roughly 2–3 years of runway to achieve key clinical readouts before further funding is needed. Upcoming 2027 data from all three lead programs will be pivotal in validating KARD's hypotheses and informing future capital allocation.

Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification

ニュートラル

Kardigan to Present at Two September Investor Conferences

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan will participate in two upcoming investor conferences: 2026 Cantor Global Healthcare Conference and Baird's 2026 Global Healthcare Conference.

Kardigan to Present at Two September Investor Conferences

ニュートラル

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #CVD--Kardigan™, Inc. (Nasdaq: KARD) today reported financial results from the second quarter ended June 30, 2026, and provided recent business updates.

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

ニュートラル

Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced the closing of its initial public offering.

Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています